financetom
Business
financetom
/
Business
/
Oracle's Long-Term Outlook Likely Disappointed Some Investors, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oracle's Long-Term Outlook Likely Disappointed Some Investors, UBS Says
Oct 17, 2025 1:21 PM

04:12 PM EDT, 10/17/2025 (MT Newswires) -- Oracle's (ORCL) long-term outlook may have disappointed some investors, but there are reasons to own the cloud computing company's stock, UBS Securities said in a Friday note.

Shares of Oracle declined 6.9% on Friday after the company said on Thursday it was aiming for earnings of $21 per share by fiscal 2030 and $225 billion in revenue, representing five-year compound annual growth rates of 28% and more than 31%, respectively.

The company anticipates signing "more large scale opportunities" over the next 12 months, Principal Financial Officer Doug Kehring said during a meeting with financial analysts.

The EPS guide may have fallen short of some investor expectations, with the real upside starting in fiscal 2029, UBS analysts Karl Keirstead and Radi Sultan wrote. "The EPS guide likely assumes that the financing options/backdrop remain very favorable, which could change," they said.

Oracle is targeting $166 billion in cloud infrastructure revenue by 2030, which is $22 billion higher than the previous target, according to UBS.

However, the guidance raise begins in fiscal 2028, which means it will likely be relatively unchanged for 2026 and 2027, Keirstead and Sultan wrote.

"Oracle needs to stand up material (artificial intelligence) infra capacity and is thereby exposed to various unforeseen go-live bottlenecks," they said.

The updated guidance comes five weeks after Oracle provided backlog metrics that were "far above" Wall Street's expectations, according to the UBS report.

"Oracle and its customers need to deliver, but we remain buy-rated on a belief that the stock can move higher as it executes on this guide acceleration," the analysts said, referring to Microsoft-backed (MSFT) OpenAI, Meta Platforms (META) and xAI as Oracle's clients.

UBS provided several factors supporting a bull case, including upside potential and more visibility on the AI front.

"Oracle hasn't even begun its acceleration," Keirstead and Sultan wrote. "In our view, the stock isn't pricing in the entire upside from the acceleration."

Oracle now has better line-of-sight to AI infra capacity coming online, while the software-as-a-service business could benefit from the company "moving AI features from free-to-paid, the re-org of the sales team and becoming more flexible on pricing/contracting," according to the report.

Price: 289.60, Change: -23.40, Percent Change: -7.48

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Greece warns shipping fleet of heightened risks after Black Sea drone attacks
Greece warns shipping fleet of heightened risks after Black Sea drone attacks
Mar 11, 2026
* Two Greek-operated tankers attacked by drones this week * Greece tells shipping fleet to update security measures * War insurance costs up for ships sailing to Black Sea (Updates with latest advisory in paragraphs 1 and 4) By Renee Maltezou, Yannis Souliotis and Jonathan Saul ATHENS, Jan 15 (Reuters) - Greece has warned ‌its shipping fleet to upgrade security...
Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026
Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026
Mar 11, 2026
The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson ( BDX ) and Company’s new breast biopsy system. The FDA approved BD’s EnCor EnCompass Breast Biopsy and Tissue Removal System, which is expected to hit the market in early 2026. This system is designed to enhance the biopsy experience by allowing clinicians to perform procedures...
OS Therapies Bone Cancer Trial Data Strengthens FDA Case
OS Therapies Bone Cancer Trial Data Strengthens FDA Case
Mar 11, 2026
OS Therapies Incorporated ( OSTX ) shares are down on Thursday following the announcement of positive biomarker data from its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, a type of bone cancer. OST-HER2, the company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting...
Equinor's Empire Wind Granted Injunction to Resume Construction
Equinor's Empire Wind Granted Injunction to Resume Construction
Mar 11, 2026
12:36 PM EST, 01/15/2026 (MT Newswires) -- Equinor ( EQNR ) said Thursday that the US District Court for the District of Columbia has granted its Empire Wind project a preliminary injunction, allowing construction to resume and temporarily blocking the Interior Department's Dec. 22, 2025 suspension. The wind project, off the coasts of New York and New Jersey, is more...
Copyright 2023-2026 - www.financetom.com All Rights Reserved